CITIGROUP INC - INTRA CELLULAR THERAPIES INC ownership

INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 55 filers reported holding INTRA CELLULAR THERAPIES INC in Q2 2014. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
CITIGROUP INC ownership history of INTRA CELLULAR THERAPIES INC
ValueSharesWeighting
Q3 2023$523,245
-77.9%
10,045
-73.1%
0.00%
-100.0%
Q2 2023$2,365,002
+279.2%
37,350
+224.3%
0.00%
Q1 2023$623,700
+29.5%
11,518
+26.5%
0.00%
Q4 2022$481,677
-3.5%
9,102
-15.3%
0.00%
Q3 2022$499,000
-48.5%
10,742
-36.6%
0.00%
-100.0%
Q2 2022$968,000
-79.1%
16,951
-77.6%
0.00%
-66.7%
Q1 2022$4,641,000
+274.6%
75,840
+220.3%
0.00%
+200.0%
Q4 2021$1,239,000
-50.5%
23,676
-64.7%
0.00%0.0%
Q3 2021$2,503,000
+24.3%
67,147
+36.1%
0.00%0.0%
Q2 2021$2,014,000
+78.1%
49,349
+48.2%
0.00%0.0%
Q1 2021$1,131,000
-33.4%
33,303
-37.7%
0.00%0.0%
Q4 2020$1,699,000
+479.9%
53,425
+367.3%
0.00%
Q3 2020$293,000
-67.0%
11,432
-67.0%
0.00%
-100.0%
Q2 2020$889,000
+117.4%
34,607
+30.1%
0.00%
Q1 2020$409,000
-20.9%
26,591
+76.3%
0.00%
Q4 2019$517,000
+341.9%
15,084
-3.7%
0.00%
Q3 2019$117,000
-44.0%
15,656
-2.7%
0.00%
Q2 2019$209,000
+14.2%
16,084
+7.0%
0.00%
Q1 2019$183,000
-28.8%
15,025
-33.5%
0.00%
Q4 2018$257,000
-37.2%
22,585
+19.7%
0.00%
Q3 2018$409,000
+25.8%
18,866
+2.6%
0.00%
Q2 2018$325,000
-12.4%
18,386
+4.4%
0.00%
Q1 2018$371,000
+57.9%
17,603
+8.5%
0.00%
Q4 2017$235,000
+13.0%
16,223
+23.0%
0.00%
Q3 2017$208,000
-3.7%
13,188
-24.2%
0.00%
Q2 2017$216,000
+1.4%
17,395
+32.8%
0.00%
Q1 2017$213,000
-12.7%
13,100
-19.0%
0.00%
Q4 2016$244,000
-58.4%
16,172
-58.0%
0.00%
Q3 2016$586,000
-11.7%
38,498
+125.2%
0.00%
-100.0%
Q2 2016$664,000
-37.0%
17,098
-54.9%
0.00%0.0%
Q1 2016$1,054,000
-53.8%
37,916
-10.6%
0.00%
-50.0%
Q4 2015$2,282,000
+282.9%
42,417
+185.1%
0.00%
+100.0%
Q3 2015$596,000
+508.2%
14,878
+382.7%
0.00%
Q2 2015$98,000
+32.4%
3,082
-0.3%
0.00%
Q1 2015$74,000
-14.9%
3,092
-37.3%
0.00%
Q4 2014$87,000
+987.5%
4,935
+730.8%
0.00%
Q3 2014$8,000
+300.0%
594
+312.5%
0.00%
Q2 2014$2,0001440.00%
Other shareholders
INTRA CELLULAR THERAPIES INC shareholders Q2 2014
NameSharesValueWeighting ↓
Sarissa Capital Management LP 640,000$25,626,0006.33%
Redmile Group, LLC 1,322,592$52,957,0004.01%
SENZAR ASSET MANAGEMENT, LLC 556,224$22,271,209,0003.24%
RA Capital Management 314,349$12,587,0001.81%
WALL STREET ASSOCIATES 205,657$8,235,0001.58%
Parametrica Management Ltd 5,400$216,0001.36%
Rhenman & Partners Asset Management AB 165,000$6,607,0001.05%
EAM Investors, LLC 95,168$3,811,0000.60%
Rock Springs Capital Management LP 180,000$7,207,0000.58%
WASATCH ADVISORS LP 1,085,973$43,482,0000.58%
View complete list of INTRA CELLULAR THERAPIES INC shareholders